Adynovate Approval History
- FDA approved: Yes (First approved November 13th, 2015)
- Brand name: Adynovate
- Generic name: antihemophilic factor (recombinant) pegylated
- Company: Baxalta Incorporated
- Treatment for: Hemophilia A
Adynovate (antihemophilic factor (recombinant) pegylated) is a human antihemophilic factor indicated for the control and prevention of bleeding episodes in patients with hemophilia A.
Development History and FDA Approval Process for Adynovate
|Dec 27, 2016||Shire Announces FDA Approval of Adynovate [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical Settings|
|Nov 13, 2015||FDA Approves Adynovate Modified Antihemophilic Factor for Hemophilia A|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.